(Q53217895)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

0 references

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Angela Cioffi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Angela Cioffi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sebastian Bauer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

18

Peter Hohenberger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

13

Axel Le Cesne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

16

Sandrine Marreaud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

17

Monia Ouali

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

9

Viktor Grünwald

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

Patrick Schöffski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

8

Anders Krarup-Hansen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Isabelle Laure Ray-Coquard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nguyen Bin Bui

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Joerg Thomas Hartmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Herlinde Dumez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jantien Wanders

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Carolyn Hayward

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Raf Sciot

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

19 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1045-1052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21937277%20AND%20SRC:MED&resulttype=core&format=json

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Reproducibility of a histopathologic grading system for adult soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970230-3

7 January 2021